Literature DB >> 3162004

Penetration of hematoporphyrin derivative into rat brain and intracerebral 9L glioma tissue.

D P Boisvert, J D McKean, J Tulip, J Cummins, M K Cheng.   

Abstract

Brain and glioma tissue levels of tritiated hematoporphyrin derivative (3H-HPD) were measured in normal and 9L intracerebral glioma-bearing rats at 24 hours following administration of 3H-HPD 2-20 mg/kg and at 24-120 hours after 3H-HPD 10 mg/kg. Levels of 3H-HPD in blood, liver, spleen and muscle were also measured. Tissue levels of 3H-HPD increased progressively as the dose was increased. In animals given 10 mg/kg, gradual decreases in tissue levels occurred between 24 and 72 hours but thereafter remained stable. The 3H-HPD level in gliomas was consistently 2-3 X greater than in brain tissue, despite changes in dosage and time interval. High levels of activity were measured in normal brain tissue at all dosage levels, and subsequent clearance of the 3H-HPD from brain, glioma, and other tissues was slow; at 120 hours after administration of 10 mg/kg, approximately 50% of the 24 hour level was still present. These results indicate that although a dose- and time-independent preferential uptake of hematoporphyrin derivative occurs in intracerebral gliomas, persistent high levels may be present in the surrounding brain. The disadvantages of using hematoporphyrin derivative rather than its individual components in studies of HPD uptake and photosensitization in the brain are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3162004     DOI: 10.1007/bf02228886

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  Quantitation of hematoporphyrin derivative in human gliomas, experimental central nervous system tumors, and normal tissues.

Authors:  R E Wharen; R E Anderson; E R Laws
Journal:  Neurosurgery       Date:  1983-04       Impact factor: 4.654

2.  Variability in hematoporphyrin derivative preparations.

Authors:  T J Dougherty
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

3.  Photoradiation therapy in the treatment of malignant brain tumors: a phase I (feasibility) study.

Authors:  E R Laws; D A Cortese; J H Kinsey; R T Eagan; R E Anderson
Journal:  Neurosurgery       Date:  1981-12       Impact factor: 4.654

4.  Permeability of different experimental brain tumor models to horseradish peroxidase.

Authors:  D R Groothuis; J M Fischer; G Lapin; D D Bigner; N A Vick
Journal:  J Neuropathol Exp Neurol       Date:  1982-03       Impact factor: 3.685

5.  Effects of photoradiation therapy on normal rat brain.

Authors:  M K Cheng; J McKean; D Boisvert; J Tulip; B W Mielke
Journal:  Neurosurgery       Date:  1984-12       Impact factor: 4.654

6.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue.

Authors:  C J Gomer; T J Dougherty
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

7.  Development of a protocol for photoradiation therapy of malignant brain tumors: part 1. Photosensitization of normal brain tissue with hematoporphyrin derivative.

Authors:  D E Rounds; S Jacques; C H Shelden; C A Shaller; R S Olson
Journal:  Neurosurgery       Date:  1982-10       Impact factor: 4.654

8.  Photoradiation therapy for the treatment of malignant tumors.

Authors:  T J Dougherty; J E Kaufman; A Goldfarb; K R Weishaupt; D Boyle; A Mittleman
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

9.  Phototherapy of human tumours using haematoporphyrin derivative.

Authors:  I J Forbes; P A Cowled; A S Leong; A D Ward; R B Black; A J Blake; F J Jacka
Journal:  Med J Aust       Date:  1980-11-01       Impact factor: 7.738

10.  Laser photoradiation therapy of cancer following hematoporphyrin sensitization.

Authors:  A G Wile; A Dahlman; R G Burns; M W Berns
Journal:  Lasers Surg Med       Date:  1982       Impact factor: 4.025

View more
  3 in total

1.  Photoradiation therapy of 9L-gliosarcoma in rats: hematoporphyrin derivative (types I and II) followed by laser energy.

Authors:  M K Cheng; J McKean; B Mielke; J Tulip; D Boisvert
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

2.  Selective incorporation of 111In-labeled PHOTOFRIN by glioma tissue in vivo.

Authors:  H T Whelan; L H Kras; K Ozker; D Bajic; M H Schmidt; Y Liu; L A Trembath; F Uzum; G A Meyer; A D Segura
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy.

Authors:  L Lilge; M C Olivo; S W Schatz; J A MaGuire; M S Patterson; B C Wilson
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.